Structure Therapeutics, Inc. Sponsored ADR ( (GPCR)) has released its Q3 earnings. Here is a breakdown of the information Structure Therapeutics, Inc. Sponsored ADR presented to its investors.
Placebo-adjusted mean weight loss of 11.3% (27.3 lbs) with 120 mg dose in the 36-week Phase 2b ACCESS study with a 10.4% adverse event-related treatment discontinuation Placebo-adjusted mean weight ...
Strong financial position with cash, cash equivalents and short-term investments of $786.5 million as of June 30, 2025 expected to fund projected operations and key clinical milestones through at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback